Liminatus Pharma (LIMN) vs Propanc Biopharma (PPCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Liminatus Pharma is the larger company by market cap ($5.0 million vs $4.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIMN | PPCB |
|---|---|---|
| Share price | $3.69 | $0.471 |
| Market cap | $4.96M | $4.63M |
| 1-day change | -4.65% | -5.55% |
| EPS (TTM) | $-23.50 | $-17.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $141.50 | $48.75 |
| 52-week low | $3.29 | $0.46 |
| Distance from 52-week high | -97.39% | -99.03% |
| Average volume | 453.28K | 1.79M |
| Shares outstanding | 1.34M | 9.83M |
| Employees | 1 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Healthcare · Biotechnology · 1 employees
About Propanc Biopharma
PPCB stock →Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Healthcare · Biotechnology · 2 employees
LIMN vs PPCB FAQ
Which is bigger, Liminatus Pharma or Propanc Biopharma?
Liminatus Pharma (LIMN) is larger, with a market capitalization of $4.96M compared with $4.63M for Propanc Biopharma (PPCB).
Are Liminatus Pharma and Propanc Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.